Search - tctmd.com

Displaying 1 - 20 of 52

Sort: Relevancy | Date

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

News Daily News

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

December 16, 2025

October 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

October 25, 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

August 31, 2025

FDA Approves Triple Therapy Polypill for High Blood Pressure

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

News Conference News AHA 2024

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

November 22, 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

April 11, 2024

Antihypertensives Linked to Lower Long-term Dementia Risk

News Daily News

Antihypertensives Linked to Lower Long-term Dementia Risk

April 01, 2024

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

Long-term ALLHAT Data Affirm Parity of Antihypertensive Meds

News Daily News

Long-term ALLHAT Data Affirm Parity of Antihypertensive Meds

December 06, 2023

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

News Daily News

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

September 12, 2023

Hypertension Drug Effects Differ From Person to Person, PHYSIC Trial Shows

News Daily News

Hypertension Drug Effects Differ From Person to Person, PHYSIC Trial Shows

April 12, 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

March 08, 2023

European Societies Define Best Practices for Performing Renal Denervation

News Daily News

European Societies Define Best Practices for Performing Renal Denervation

February 21, 2023

February 2023 News Roundup

News Opinion CV Team Dispatch

February 2023 News Roundup

February 15, 2023

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

News Daily News

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

November 16, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.